Actively Recruiting

Phase 1
Phase 2
Age: 6Years - 40Years
All Genders
NCT01542879

Development of Radiation Free Whole Body Magnetic Resonance (MR) Imaging Technique for Staging Children With Cancer

Led by Heike E Daldrup-Link · Updated on 2024-11-25

75

Participants Needed

1

Research Sites

773 weeks

Total Duration

On this page

AI-Summary

What this Trial Is About

A research study on the diagnosis of spread of disease for children who have been diagnosed with solid tumors using a new whole body imaging technique and a new MR contrast agent (ferumoxytol). Standard tests that are used to determine the extent and possible spread of a child's disease include magnetic resonance (MR) imaging, computed tomography (CT), Positron Emission Tomography (PET) as well as bone scanning, and metaiodobenzylguanidine (MIBG) scanning. The purpose of this study is to determine if newer imaging tests referred to as whole body diffusion-weighted MR and whole body PET/MR can detect the extent and spread of the disease as accurately or even better as the standard tests (CT, MR and/or PET/CT). The advantage of the new imaging test is that it is associated with no or significantly reduced radiation exposure compared to standard CT and PET/CT imaging tests. The results of whole body MR and PET/MR will be compared with that of the conventional, standard imaging studies for tumor detecting.

CONDITIONS

Official Title

Development of Radiation Free Whole Body Magnetic Resonance (MR) Imaging Technique for Staging Children With Cancer

Who Can Participate

Age: 6Years - 40Years
All Genders

Eligibility Criteria

Eligible

You may qualify if you...

  • Diagnosis of a solid extra-cranial tumor like malignant lymphoma or malignant sarcoma
  • Scheduled for or completed a 18F-FDG-PET or 18F-FDG-PET/CT tumor staging procedure
  • No restrictions on prior treatment
  • Participant or parent/guardian consented, with assent from minors as appropriate
Not Eligible

You will not qualify if you...

  • MR-incompatible metal implants
  • Need for sedation or claustrophobia
  • Hemosiderosis or hemochromatosis (except for inclusion in a study branch without ferumoxytol)
  • Iron overload preventing use of ferumoxytol
  • History of allergic reactions to iron compounds or severe allergies
  • Pregnant women and fetuses

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Trial Site Locations

Total: 1 location

1

Stanford University Cancer Institute

Stanford, California, United States, 94305

Actively Recruiting

Loading map...

Research Team

L

Lucia Barrato

CONTACT

How is the study designed?

Study Type

INTERVENTIONAL

Masking

NONE

Allocation

NA

Model

SINGLE_GROUP

Primary Purpose

DIAGNOSTIC

Number of Arms

1

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here